CYCLOPHOSPHAMIDE, CISPLATIN, AND LEUPROLIDE ACETATE IN PATIENTS WITH DEBULKED STAGE-III OR STAGE-IV OVARIAN-CARCINOMA

A phase II study of cyclophosphamide, cisplatin, and leuprolide acetat e after debulking of stage III or IV ovarian carcinoma was conducted i n 33 patients through a cooperative group study involving 11 instituti ons. The intent was to determine whether the addition of a gonadotropi n-releasing hormone analogue would alter the response rates and toxici ty profile of cyclophosphamide and cisplatin in patients with advanced ovarian cancer. Twenty-nine patients completed all 6 planned cycles. Of the 19 patients who had second-look laparotomy, 12 had persistent d isease and 7 were negative for disease. The use of a gonadotropin-rele asing hormone with combined chemotherapy did not alter the toxicity pr ofile or the effectiveness of chemotherapy when comparisons were made with historical controls. (C) 1994 Academic Press, Inc.